Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Active not recruiting 4Completed 3

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 2NET 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Carboplatin 18Cisplatin 14pembrolizumab 13durvalumab 11Pemetrexed 11Paclitaxel 11Nivolumab 11Gemcitabine 11Rituximab 9trastuzumab deruxtecan 7osimertinib 6olaparib 6Dexamethasone 6Capecitabine 6atezolizumab 5acalabrutinib 5Specimen Handling 5Lenalidomide 5Bevacizumab 5130-nm albumin-bound paclitaxel 5tremelimumab 4niraparib 4cabozantinib 4amivantamab 4Prednisone 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × cabozantinib × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Exelixis

Phase 3 Active not recruiting
187 enrolled 13 charts 1 FDA
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03141177 2025-06-06

CheckMate 9ER

Bristol-Myers Squibb

Phase 3 Active not recruiting
701 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡